Cancer Research Journal

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

Research Article |

Prognosis of Breast Cancer in Relation with Estrogen-Progesterone and HER-2 Receptor Status

Introduction: Worldwide, breast cancer is the second most common cause of death. The occurrence of breast cancer is roughly 2.3 million women of all ages worldwide. Both the normal breast cells and some breast cancer cells have the receptors that attach to the estrogen and progesterone hormone and play vital roles for normal and even abnormal growth of breast cells. The aim of this study was to evaluate the prognosis of breast cancer in relation with receptor status. Methods: This prospective observational study was carried out in the Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh during the period from December 2011 to December 2021. In total 100 breast cancer patients of several stages and grades were enrolled in this study as study subjects. Proper written consents were taken from all the participants before data collection. All data were processed, analyzed and disseminated by using MS Excel and SPSS version 25.0 as per need. Result: In this study, among total 100 cases, estrogen receptors were analyzed in 88 cases; among them in majority (86%), positive estrogen receptors were found whereas negative receptors were found in 14% cases. Progesterone receptors were analyzed in 85 cases; among them in majority (69%), positive progesterone receptors were found whereas negative receptors were found in 31% cases. HER 2 receptors were analyzed in 52 cases; among them in majority (67%), negative HER 2 receptors were found whereas positive receptors were found in 33% cases. highest death (12%) occurred in patients with ER-/PR-. In contrast, no death was seen in ER+/PR+ patients. In comparing the estrogen receptor status among participants, we did not find any significant correlation considering the stages or grades of carcinoma; the P values were >0.05. Conclusion: This study concluded that, compared to women of breast cancer with ER+/PR+ tumors, women with ER+/PR-, ER-/PR+, or ER-/PR- tumors experienced higher risks of mortality and distant metastasis. Receptor status of breast cancer may be considered as potential indicator for proper management of patients with breast cancer. Preliminary diagnosis and treatment of breast cancers have a certain survival advantage. Thus, we should need to assess the hormone receptor status for every patient before commencing treatment. To get robust data, multicenter studies are in great need of policymakers to interpret the demonstrable scenario and to take necessary steps towards mitigating this problem.

Receptors, Diagnosis, Breast Carcinoma, Tumors, Oncology

APA Style

Nahar, S., Mollah, N. U., Haque, M. S., Uddin, M. J., Alam, S., et al. (2023). Prognosis of Breast Cancer in Relation with Estrogen-Progesterone and HER-2 Receptor Status. Cancer Research Journal, 11(4), 156-160.

ACS Style

Nahar, S.; Mollah, N. U.; Haque, M. S.; Uddin, M. J.; Alam, S., et al. Prognosis of Breast Cancer in Relation with Estrogen-Progesterone and HER-2 Receptor Status. Cancer Res. J. 2023, 11(4), 156-160. doi: 10.11648/j.crj.20231104.15

AMA Style

Nahar S, Mollah NU, Haque MS, Uddin MJ, Alam S, et al. Prognosis of Breast Cancer in Relation with Estrogen-Progesterone and HER-2 Receptor Status. Cancer Res J. 2023;11(4):156-160. doi: 10.11648/j.crj.20231104.15

Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. globocan iarc fr/Default aspx 2014; 2013.
2. Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Periañez AM, Tonkin K, Deleu I, Sohn J. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. The Lancet Oncology. 2020 Jan 1; 21(1): 60-72.
3. American Cancer Society. Breast Cancer Facts & Figures 2017–2018. Atlanta: American Cancer Society I; 2018.
4. Breast Cancer. World Health Organization (WHO). [Available at:] [Last Accessed on: 12-12-2022]
5. Forazy MA. Healthcare. [Available at:] [Last Accessed on: 16-11-2022]
6. Types of Breast Cancer. [Available at: Donate] [Last Accessed on: 12-12-2022]
7. Abdulkareem IH, Zurmi IB. Review of hormonal treatment of breast cancer. Nigerian journal of clinical practice. 2012; 15(1)
8. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC. Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012 Nov 15; 118(22): 5463-72.
9. Pauklin S, Sernández IV, Bachmann G, Ramiro AR, Petersen-Mahrt SK. Estrogen directly activates AID transcription and function. Journal of Experimental Medicine. 2009 Jan 16; 206(1): 99-111.
10. Trabert B, Sherman ME, Kannan N, Stanczyk FZ. Progesterone and breast cancer. Endocrine reviews. 2020 Apr; 41(2): 320-44.
11. Srivastava S, Koay EJ, Borowsky AD, De Marzo AM, Ghosh S, Wagner PD, Kramer BS. Cancer overdiagnosis: a biological challenge and clinical dilemma. Nature Reviews Cancer. 2019 Jun; 19(6): 349-58.
12. Cancer Grade. Breast Cancer New. [Available at:] [Last Accessed on: 16-11-2022]
13. Mukherjee D, Zhao J. The role of chemokine receptor CXCR4 in breast cancer metastasis. American journal of cancer research. 2013; 3(1): 46.
14. Ginsburg O, Yip CH, Brooks A, Cabanes A, Caleffi M, Dunstan Yataco JA, Gyawali B, McCormack V, McLaughlin de Anderson M, Mehrotra R, Mohar A. Breast cancer early detection: A phased approach to implementation. Cancer. 2020 May 15; 126: 2379-93.
15. Schüz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S, Romieu I, Segnan N, Wardle J, Wiseman M, Belardelli F. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer epidemiology. 2015 Dec 1; 39: S1-0.
16. Ahuja R, Chauhan N, Saini S, Harsh M. Expression of Ki67 as a Prognostic Marker in Invasive Breast Carcinoma. National Journal of Laboratory Medicine. 2017.
17. Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, Oliveira CE, Watanabe MA. Molecular markers for breast cancer: prediction on tumor behavior. Disease markers. 2014 Oct; 2014.
18. Yan B, Yang LM, Hao LP, Yang C, Quan L, Wang LH, Wu Z, Li XP, Gao YT, Sun Q, Yuan JM. Determinants of quality of life for breast cancer patients in Shanghai, China. PloS one. 2016 Apr 15; 11(4): e0153714.
19. Chen HL, Zhou MQ, Tian W, Meng KX, He HF. Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database. PloS one. 2016 Oct 31; 11(10): e0165409.
20. Sariego J. Breast cancer in the young patient. The American surgeon. 2010 Dec; 76(12): 1397-400.
21. Liedtke C, Rody A, Gluz O, Baumann K, Beyer D, Kohls EB, Lausen K, Hanker L, Holtrich U, Becker S, Karn T. The prognostic impact of age in different molecular subtypes of breast cancer. Breast cancer research and treatment. 2015 Aug; 152(3): 667-73.
22. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL. Breast cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022 Oct 3.
23. Li CI. Risk of mortality by histologic type of breast cancer in the United States. Hormones and Cancer. 2010 Jun; 1(3): 156-65.
24. Metzger‐Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, Vaz‐Luis I, Hughes ME, Winer EP, Lin NU. Mixed invasive ductal and lobular carcinoma of the breast: prognosis and the importance of histologic grade. The oncologist. 2019 Jul; 24(7): e441-9.
25. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA oncology. 2020 May 1; 6(5): 676-84.
26. Özmen V. Breast cancer in Turkey: clinical and histopathological characteristics (analysis of 13.240 patients). The journal of breast health. 2014 Apr; 10(2): 98.
27. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population‐based study. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2004 Jul 1; 101(1): 51-7.
28. Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu‐Khalaf MM, DiGiovanna MP, Sanft TB, Pusztai L, Gross CP, Chagpar AB. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015 Aug 1; 121(15): 2544-52.
29. Yip CH, Rhodes A. Estrogen and progesterone receptors in breast cancer. Future oncology. 2014 Nov; 10(14): 2293-301.
30. Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast cancer research and treatment. 2005 Mar; 90(1): 65-70.
31. Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, Beck AH. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Research. 2013 Aug; 15(4): 1-3.
32. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast cancer research. 2007 Feb; 9: 1-0.